> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Genmab Filing BLA for Large B-cell Lymphoma Therapy
- URL: https://www.fdaweb.com/genmab-filing-bla-for-large-b-cell-lymphoma-therapy/
- Published: 2022-07-01T12:00:00.000Z
- Updated: 2026-09-14T17:50:54.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5152222

Genmab says it will submit in the second half of this year a BLA for subcutaneous epcoritamab, an investigational bispecific antibody for treating patients with relapsed/refractory large B-cell lymphoma. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of CD20+ cells, according to the company. 

The submission will be based on data from the company’s EPCORE NHL-1 open-label, multi-center trial evaluating the safety and preliminary efficacy of epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin lymphoma, Genmab says. In April , Genmab and AbbVie announced the [topline](https://www.globenewswire.com/Tracker?data=CRgETGM-oqY%5FPP0xwLUNBVg9nebwRUSDOM2luKF2WxsVg9VVg3AD8lDhWQC5wH-b9xsveuYfRCI8nY-q4n1wWRg1Ca2H7MJ64Sl3JJ34Xi0VRvHexA2MTcEW4TRpNL7-iLCovPaFvdDeKUGtd8KTo%5FO5Cxb0-WFDL7GoUXzl0kM7YAdvogBj3c7nLE1rr%5FJTvwy90EPCKRCyjQfaSVac6EgbkTzcgZ-57WYhHWWn7t4MMsoOoktJPBmX8nmD9qahzC-iIcarRQJRlEsPb-mBYJJqEc3xMXeQW8zpI4ABVf9ozM6CU3skDtITAOy2GxJgZKPIxinmGvwkc821Kvqbe9oeV0DRdNfcrvp629ZyfXs=&ref=fdaweb.com) results, and last month [primary](https://www.globenewswire.com/Tracker?data=u4PLAYEoFZyJ4HDx7IlMcaj3A5wVKH3vvnkTT6aYBi2OvWCY9B15qEbAvFJqz8AZwZtCjwzdC9TP9FUCO8U4bNjeB4Gg14e0Za6obHHQ0CwXlG%5Fq%5FGDQ4xUyfMQlQXvKgth3qfkEFQRNymwh23RtdY95Ls2ZknrvhDSDTU3CYt7zKgknF9Cjjh0Tw5TnaD4JWbjARcLDIJ5X9xvu8mP4v36%5Fuw1kV3HwK6ggZPO15%5F42htW0RupzIA%5FxAuw9NVhvBxH6OWz3qXNRT2MCGIF5n1ztSapnp-S1iI8CeSQaV5EfVp8gvl6qskAD8tRB9kFyw8fPxqynHDHlU9e%5FvTer%5FE1DxhEsQ2T9NlEA0YUjQu5RLfN6kzoKOouByRDU%5F4HF&ref=fdaweb.com) results were presented at the annual meeting of the European Hematology Association in Vienna, Austria.